Author

Gracemarie Bricalli

Observed name: G. Bricalli

Institution: European Society for Medical Oncology

Observed institution: European Society for Medical Oncology

ORCID: 0000-0002-0265-7087

Observed ORCID: 0000-0002-0265-7087

OpenAlex ID: A5071973484

Global cancer control: responding to the growing burden, rising costs and inequalities in access

2018 · Gerald W. Prager, Sofia Braga, et al. · ESMO Open · 333

ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe

2023 · A. Bayle, J. Bonastre, et al. · Annals of Oncology · 129

Access to essential anticancer medicines for children and adolescents in Europe

2020 · G. Vassal, O. Kozhaeva, et al. · Annals of Oncology · 78

Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?

2019 · Alexandru Eniu, Nathan I. Cherny, et al. · ESMO Open · 48

ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update

2025 · N.I. Cherny, D. Trapani, et al. · Annals of Oncology · 39

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

2016 · C. Dittrich, M. Kosty, et al. · Annals of Oncology · 19

Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines

2016 · Alexandru Eniu, Julie Torode, et al. · ESMO Open · 15

ESMO and WHO: 14 years of working in partnership on cancer control

2016 · Andreas Ullrich, Fortunato Ciardiello, et al. · ESMO Open · 4

Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain

2023 · F. Roitberg, T. Amaral, et al. · ESMO Open · 3

Reply to the Letter to the Editor regarding ‘Overcoming Barriers in Biomarker Testing’ J. García-Foncillas et al.

2024 · A. Bayle, D. Chaltiel, et al. · Annals of Oncology

Works count: 10

Citation count: 668

H-index: 7

I10-index: 7